Cargando…
Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
Background: In the first-line treatment of biliary tract cancers (BTCs), XELOX (capecitabine plus oxaliplatin) showed comparable clinical efficacy and safety to gemcitabine and oxaliplatin (GEMOX), with fewer visits and better treatment management. Our study aims to investigate the cost-effectivenes...
Autores principales: | Chen, Ruijia, Zhang, Yalan, Lin, Kongying, Huang, Defu, You, MaoJin, Lai, Yanjin, Wang, Jinye, Hu, Yingying, Li, Na |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354395/ https://www.ncbi.nlm.nih.gov/pubmed/35935821 http://dx.doi.org/10.3389/fphar.2022.871262 |
Ejemplares similares
-
Immune checkpoint inhibitors plus capecitabine and oxaliplatin in unresectable or advanced biliary tract cancer patients: A retrospective study
por: Zhao, Jie, et al.
Publicado: (2022) -
Capecitabine Plus Oxaliplatin Combination Therapy for Basal Cell Carcinoma
por: Rhee, Jiyoung, et al.
Publicado: (2019) -
Outpatient chemotherapy with gemcitabine and oxaliplatin in patients with biliary tract cancer
por: Harder, J, et al.
Publicado: (2006) -
Treatment of Patients with Advanced Biliary Tract Cancer with Either Oxaliplatin, Gemcitabine, and Capecitabine or Cisplatin and Gemcitabine—A Randomized Phase II Trial
por: Markussen, Alice, et al.
Publicado: (2020) -
Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer
por: Peng, Jingyuan, et al.
Publicado: (2018)